keyword
MENU ▼
Read by QxMD icon Read
search

uterine leiomyosarcoma

keyword
https://www.readbyqxmd.com/read/28804663/misdiagnosis-of-a-giant-uterine-leiomyosarcoma-clinic-and-image-challenges
#1
Jila Agah, Sedighe Karimzadeh, Fateme Moharrer Ahmadi
A 41-year-old woman (G3P2L2Ab1) was referred to gynecology clinic with chief complaints of abdominal distension and localized abdominal wall pruritus for three months. She was misdiagnosed with gastrointestinal disorder and ultimately had undergone imaging. Ultrasonography and computed tomography (CT) scan disclosed a huge solid-cystic mass originating from the ovary. On clinical examination the patient had no pain or tenderness and no gynecologic complaints. Laboratory tests showed normal tumor markers and hemoglobin at 8 g/dl...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28747255/adjuvant-gemcitabine-docetaxel-chemotherapy-for-stage-i-uterine-leiomyosarcoma-trends-and-survival-outcomes
#2
Ramey D Littell, Lue-Yen Tucker, Tina Raine-Bennett, Ted E Palen, Eve Zaritsky, Romain Neugebauer, Julia Embry-Schubert, Scott E Lentz
OBJECTIVE: To assess recent trends of administering adjuvant gemcitabine-docetaxel (GD) chemotherapy for Stage I uterine leiomyosarcoma, and to compare disease-free and overall survival between women who received and did not receive adjuvant GD chemotherapy. METHODS: All patients diagnosed with Stage I uterine leiomyosarcoma in a California-Colorado population-based health plan inclusive of 2006-2013 were included in a retrospective cohort. Adjuvant GD chemotherapy rates, clinico-pathologic characteristics and survival estimates were assessed...
July 24, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28747229/vaginal-metastasis-as-the-initial-presentation-of-leiomyosarcoma-a-case-report
#3
Cecilia Villalaín-González, Álvaro Tejerizo-García, Patricia Lopez-Garcia, Gregorio López-González, Ma Reyes Oliver-Perez, Jesús S Jiménez-López
BACKGROUND: Uterine leiomyosarcomas are very rare and highly aggressive tumors that have a high rate of recurrence and poor prognosis, even when early diagnosed. Due to their relative rarity, there is limited research on optimal management strategies. CASE PRESENTATION: A 60-year-old woman with a history of an asymptomatic uterine leiomyoma presented in October 2015 with postmenopausal bleeding and a friable vaginal cyst that bled when palpated. A partial cystectomy was performed, and malignant-like cystic and solid components were identified...
July 26, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28743407/prevalence-of-undiagnosed-uterine-leiomyosarcoma-in-women-undergoing-hysterectomy-or-myomectomy-for-benign-indications
#4
Sören Lange, Nicola Pluchino, Aurore Fehlmann, Roberto Marci, Meriem Boukrid, Inès Ben Jazia, Patrick Petignat, Jean Dubuisson
OBJECTIVE: To determine the prevalence of undiagnosed uterine leiomyosarcoma (LMS) in women undergoing hysterectomy or myomectomy for suspected benign leiomyomas. STUDY DESIGN: Retrospective, single-centre, cohort study. Information for all gynaecological procedures for suspected benign leiomyomas between 1993 and 2016 was extracted from the hospital database. The prevalence of LMS was calculated by surgery type and age group. RESULTS: The prevalence of LMS was 1...
June 21, 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28730252/morphological-imaging-and-surgical-aspects-in-a-complex-case-of-uterine-leiomyosarcoma-case-report-and-review-of-the-literature
#5
Aida TincuŢa Petca, Simona Vlădăreanu, Dan Cristian Radu, Mihaela BoŢ, Costin Berceanu, Bogdan Stelian Mastalier Manolescu, Cosmin Medar, Răzvan Cosmin Petca
Leiomyosarcoma is a rare condition so there are relatively few and small case series and no prospective studies to provide clear guidelines regarding management. We report on a case that presents some particularities that further underline diagnostic and treatment difficulties posed by the affliction of such a rare tumor. This is the case of a 43-year-old woman who had a large tumor arising from the uterus, with a spectacular growth rate over a short period. The patient, with congenital spastic tetraparesis and hydrocephalus, came for belly enlargement with rapid increase in size over the previous two months...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/28729098/a-multicentre-retrospective-review-of-clinical-characteristics-of-uterine-sarcoma
#6
Marta Wais, Elissa Tepperman, Marcus Q Bernardini, Lilian T Gien, Waldo Jimenez, Ally Murji
OBJECTIVE: Professional societies have recently urged gynaecologists to counsel patients about the risks of encountering uterine sarcoma at fibroid surgery especially when morcellation is used. Our objective was to learn the preoperative and postoperative characteristics of patients with uterine sarcoma to better counsel patients undergoing surgery for presumably benign fibroids. METHODS: This is a multicentre, retrospective cohort study. Three academic tertiary cancer centres in Southern Ontario over a 13-year period (2001-2014)...
August 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/28700435/ifitm1-outperforms-cd10-in-differentiating-low-grade-endometrial-stromal-sarcomas-from-smooth-muscle-neoplasms-of-the-uterus
#7
Aurelia Busca, Previn Gulavita, Carlos Parra-Herran, Shahidul Islam
Distinguishing between uterine neoplasms of smooth muscle and endometrial stromal origin is a frequent diagnostic challenge. We investigated the staining pattern of interferon-induced transmembrane protein-1 (IFITM1), a novel endometrial stromal marker, in endometrial and smooth muscle uterine neoplasms and compared it with CD10 in its ability to differentiate between these two groups. Immunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma...
July 11, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28696085/does-fibroids-surgery-by-endoscopy-or-laparotomy-represent-a-malignancy-threat
#8
Liselotte Mettler, Khulkar Abdusattarova, Ibrahim Alkatout
BACKGROUND: 1) to estimate the incidence of unsuspected uterine sarcoma in patients after myomectomies and hysterectomies for benign uterine fibroids. 2) to assessed the incidence of uterine sarcomas among patient who had uterine fibroids or a suspicion of uterine sarcoma before undergoing the surgical procedures. METHODS: Retrospective study in single center university hospital. Patient 's records with uterine fibroids and uterine sarcoma from 2003 to 2015 collected...
July 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28693141/effect-of-2-methoxyestradiol-on-sk-lms-1-uterine-leiomyosarcoma-cells
#9
Ji-Sun Lee, Changhwan Ahn, Hee Young Kang, Eui-Bae Jeung
An endogenous metabolite of 17β-estradiol, 2-methoxyestradiol (2-ME), has affinity for estrogen receptors. This compound was reported to be a promising antitumor drug due to its anti-proliferative effects on a wide range of tumor cell types. Numerous previous studies have been performed to evaluate the cytotoxic effects of 2-ME on tumor cell lines in following the induction of G2/M cell cycle arrest and subsequent apoptosis. Uterine leiomyosarcoma (ULMS) is a relatively rare malignant smooth muscle cell tumor that develops in the uterus muscle layer...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28691261/hyperphosphatasemia-in-leiomyosarcoma-of-the-uterus-two-case-reports-and-a-literature-review
#10
Mariko Jitsumori, Anna Umeda, Ayako Hosoi, Kazuya Miyanishi, Satoru Munakata, Toshiya Yamamoto
Some tumors are known to produce alkaline phosphatase (ALP). Seven cases of uterine leiomyosarcoma were identified from the clinical records of Sakai City Medical Center from January 2006 to December 2014. Patients' ages ranged from 47 to 75 years (median: 58). Clinical stages were IB, IIB, IIIA, and IVB in four, one, one, and one cases, respectively. Of these, two were found to have hyperphosphatasemia before surgery, and the elevated ALP level decreased after surgery, and increased with disease recurrence...
July 10, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28678537/pharmacokinetic-drug-evaluation-of-pazopanib-for-the-treatment-of-uterine-leiomyosarcomas
#11
REVIEW
Simone Ferrero, Umberto Leone Roberti Maggiore, Nicoletta Aiello, Fabio Barra, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi, Domenica Lorusso
Uterine leiomyosarcomas (ULMS) represent 1.3% of all uterine malignant tumors. Surgery is the curative treatment for patients with early stage disease. In case of advanced, persistent or recurrent tumor, chemotherapy represents the standard of care, but these patients have a poor prognosis. As the results with available therapies are far from being satisfactory, research is focusing on identification of new compounds. In 2012 the Food and Drug Administration (FDA) licensed pazopanib for the treatment of advanced soft-tissue sarcomas failing previous chemotherapy...
August 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28654693/fatty-acid-synthase-reprograms-the-epigenome-in-uterine-leiomyosarcomas
#12
Min Guan, Xiwei Wu, Peiguo Chu, Warren A Chow
SK-UT-1 uterine leiomyosarcomas (Ut-LMS) cells were transduced with a fatty acid synthase (FASN)-containing retroviral vector to recapitulate the "lipogenic phenotype of cancer." Consistent with this model, forced expression of FASN enhanced SK-UT-1 proliferation, migration, and cellular motion. Further investigation showed FASN promotes trimethylation of H3K9 (H3K9me3) and acetylation of H3K27 (H3K27ac) in SK-UT-1 cells. In contrast, siRNA targeting of FASN in high endogenous FASN expressing SK-LMS-1 Ut-LMS cells inhibits trimethylation of H3K9 and acetylation of H3K27...
2017: PloS One
https://www.readbyqxmd.com/read/28651804/efficacy-and-safety-of-trabectedin-or-dacarbazine-in-patients-with-advanced-uterine-leiomyosarcoma-after-failure-of-anthracycline-based-chemotherapy-subgroup-analysis-of-a-phase-3-randomized-clinical-trial
#13
Martee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, Kristen Ganjoo, Robin L Jones, Arthur Staddon, Daniel Rushing, Mohammed Milhem, Bradley Monk, George Wang, Sharon McCarthy, Roland E Knoblauch, Trilok V Parekh, Robert G Maki, George D Demetri
OBJECTIVE: Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in women with uterine leiomyosarcoma (uLMS), the largest subgroup of enrolled patients (40%). METHODS: Of 577 patients randomized 2:1 to receive trabectedin 1.5mg/m(2) by 24-hour IV infusion or dacarbazine 1g/m(2) by 20-120-minute IV infusion once every three weeks, 232 had uLMS (trabectedin: 144; dacarbazine: 88)...
June 23, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28647614/inefficiency-of-ulipristal-acetate-on-uterus-leiomyomas-as-an-additional-sign-to-suspect-leiomyosarcoma
#14
P Kadhel, M Smail, D Borja De Mozota
The unexpected diagnosis of a leiomyosarcoma from a surgical specimen of a presumed leiomyoma is rare, but with deleterious consequences, especially if morcellation techniques are used. There are currently no effective methods for such a preoperative diagnosis. Ulipristal acetate has demonstrated efficacy for the preoperative treatment of leiomyomas, but not for all patients. We report two cases of leiomyosarcomas in patients treated with ulipristal acetate for a presumed leiomyoma. We propose that ineffective ulipristal acetate treatment may indicate a population in which uterine leiomyosarcoma is more prevalent...
June 21, 2017: Journal of gynecology obstetrics and human reproduction
https://www.readbyqxmd.com/read/28643014/neuron-navigator-2-and-cyclin-d2-are-new-candidate-prognostic-markers-in-uterine-sarcoma
#15
Ben Davidson, Ellen Hellesylt, Arild Holth, Håvard Emil Danielsen, Tone Skeie-Jensen, Betina Katz
The objective of this study was to validate the diagnostic and clinical role of four protein products of genes previously found to be differentially expressed in uterine low-grade endometrial stromal sarcoma (LG-ESS) compared to uterine leiomyosarcoma (LMS). Protein expression by immunohistochemistry of transgelin (TGLN), neuron navigator-2 (NAV2), fatty acid binding protein-3 (FABP3), and cyclin D2 (CCND2) was analyzed in 305 uterine sarcomas (231 LMS, 74 LG-ESS). Expression was analyzed for association with clinicopathologic parameters and survival...
June 22, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28633271/rupture-of-a-metastatic-uterine-leiomyosarcoma-invading-the-right-atrium-causing-cardiac-tamponade
#16
Keijiro Katayama, Shinya Takahashi, Taijiro Sueda
No abstract text is available yet for this article.
July 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28630682/overexpressed-prame-is-a-potential-immunotherapy-target-in-sarcoma-subtypes
#17
Jason Roszik, Wei-Lien Wang, John A Livingston, Christina L Roland, Vinod Ravi, Cassian Yee, Patrick Hwu, Andrew Futreal, Alexander J Lazar, Shreyaskumar R Patel, Anthony P Conley
BACKGROUND: PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies are currently in development for other cancers such as melanoma. METHODS: To map the landscape of PRAME expression in sarcoma, we used publicly available data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) projects and determined which sarcoma subtypes and subsets are associated with increased PRAME expression...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28625393/establishment-and-characterization-of-uterine-sarcoma-and-carcinosarcoma-patient-derived-xenograft-models
#18
Tine Cuppens, Jeroen Depreeuw, Daniela Annibali, Debby Thomas, Els Hermans, Ellen Gommé, Xuan Bich Trinh, David Debruyne, Philippe Moerman, Diether Lambrechts, Frédéric Amant
OBJECTIVE: Uterine sarcomas (US) and carcinosarcomas (CS) are rare, aggressive cancers. The lack of reliable preclinical models hampers the search for new treatment strategies and predictive biomarkers. To this end, we established and characterized US and CS patient-derived xenograft (PDX) models. METHODS: Tumor fragments of US and CS were subcutaneously implanted into immunocompromised mice. Engrafted xenograft and original tumors were compared by means of histology, immunohistochemistry, whole-genome low-coverage sequencing for copy number variations, and RNA sequencing...
June 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28621321/bcor-is-a-robust-diagnostic-immunohistochemical-marker-of-genetically-diverse-high-grade-endometrial-stromal-sarcoma-including-tumors-exhibiting-variant-morphology
#19
Sarah Chiang, Cheng-Han Lee, Colin J R Stewart, Esther Oliva, Lien N Hoang, Rola H Ali, Martee L Hensley, Javier A Arias-Stella, Denise Frosina, Achim A Jungbluth, Ryma Benayed, Marc Ladanyi, Meera Hameed, Lu Wang, Yu-Chien Kao, Cristina R Antonescu, Robert A Soslow
Recognition of high-grade endometrial stromal sarcoma is important because of its aggressive clinical behavior. Morphologic features of YWHAE-NUTM2 high-grade endometrial stromal sarcoma may overlap with other uterine sarcoma types. BCOR immunoexpression was studied in these tumors and their morphologic mimics to assess its diagnostic utility. BCOR immunohistochemical staining was performed on archival tissue from 28 high-grade endometrial stromal sarcomas with classic morphology (20 YWHAE-NUTM2, 5 ZC3H7B-BCOR, 3 BCOR-ZC3H7B), 3 high-grade endometrial stromal sarcomas with unusual morphology and unknown gene rearrangement status, 66 low-grade endometrial stromal sarcomas, 21 endometrial stromal nodules, 38 uterine leiomyosarcomas, and 19 uterine leiomyomas...
June 16, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28618731/impact-of-adjuvant-treatment-on-oncologic-outcomes-in-patients-with-stage-i-leiomyosarcoma-of-the-uterus
#20
Gökhan Boyraz, Derman Başaran, M Coşkun Salman, Nejat Özgül, Kunter Yüce
BACKGROUND/AIM: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomyosarcoma (LMS). MATERIALS AND METHODS: Clinicopathological data of cases of stage I uterine LMS from 1998 to 2015 were retrieved from the computerized database of Hacettepe University Hospital. The Kaplan-Meier method was used to estimate survival and progression-free survival, and survival differences were analyzed by log-rank test. Cox regression analysis was performed to account for the potential influence of confounding factors...
June 12, 2017: Turkish Journal of Medical Sciences
keyword
keyword
89011
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"